Tag: kratom

Florida drug bust seizes 92,000 pounds of 7-OH, arsenal of guns and explosives, sheriff says: “‘Breaking Bad’ on steroids”

In what is considered the largest bust of its kind in the country, a young man is facing serious charges after a Central Florida drug and explosives seizure unveiled an operation that authorities referred to as “‘Breaking Bad’ on steroids.”

In a Facebook video shared Wednesday, Brevard County Sheriff Wayne Ivey and Palm Bay Police Chief Mariano Augello announced they arrested 26-year-old Maxwell Horvath on several charges after local and federal law enforcement agents seized approximately 92,000 pounds of an illegal substance believed to contain concentrations of 7-OH — a byproduct of the kratom plant said to be just as addictive as opioids — with a street value of around $4.7 million.

Earlier this year, Florida Attorney General James Uthmeier issued an emergency rule banning the use of 7-OH, calling it an “immediate danger.” Uthmeier is looking to have a judge toss out a challenge to a rule banning the sale and manufacture of the kratom byproduct.

“This is what danger looks like right here,” Ivey said, detailing the dozens of weapons and boxes shown throughout the video. “Everything that you see behind us, everything you see in front of us, is a red flag for disaster.”

Augello added that along with the drugs, agents seized an arsenal of firearms and explosives, including five improvised explosive devices (IEDs) on the property where the warrant was searched, along with grenade simulators and 50 pounds of precursor chemicals to make explosives.

“We’re not just talking about drugs, we’re not just talking about illegal substances out in the street, we’re talking about explosive devices,” he said. “Things that the military and other countries are utilizing all over the world to take out populations of people.”

Ivey chimed in, calling the situation “terrorist activity across the board.”

“This guy was either looking to engage in war or looking to arm those or furnish to those who are,” Ivey said.

Keep reading

Ohio governor calls kratom an imminent public health risk, pushes for ban

Ohio Gov. Mike DeWine is urging the Ohio Board of Pharmacy to classify kratom as a Schedule I drug, citing it as an “imminent public health risk” due to its potential dangers, particularly for teenagers and babies.

Kratom, which is not approved by the Food and Drug Administration, is sold in products like the Feel Free drink at gas stations and stores in Ohio and Kentucky.

The governor’s proposal would make Ohio the first state to take such strong action against kratom.

Doctors at Cincinnati Children’s Hospital are raising alarms about its risks.

Dr. Stephanie Merher, a neonatologist, said, “Some of the moms who have taken this and not taken anything else, they have actually needed to go on buprenorphine or methadone to get off of this. It’s that potent.”

She has treated babies exposed in utero who exhibit symptoms similar to opioid withdrawal, including fussiness, tremors and difficulty eating.

Dr. Shan Yin, medical director of the Cincinnati Drug and Poison Information Center, explained that kratom and kava, another ingredient in Feel Free, create a “speedball-like” effect. He noted, “It’s also at this point, unregulated. So, you never know quite what’s in it.”

Feel Free is sold as an herbal product, not a controlled substance, and carries a “21+ only” warning, which the company says it voluntarily implemented. However, that is not required under federal or Ohio law, so anyone can purchase it in the state.

Kentucky lawmakers enacted a 21-plus age limit on kratom last year, while Indiana banned it completely in 2014. Ohio currently has no restrictions.

Earlier in August, Ohio House Minority Leader Dani Isaacson (D) told WLWT he wants to protect kids from the synthetic form form of Kratom known as 7-OH. “You can buy it at convenience stores and gas stations and vape stores in super concentrated forms with no age restrictions. It’s not behind the counter. And so we need to do something about it.”

Botanic Tonics, the maker of Feel Free, disputes the safety concerns, asserting that its product contains only natural, whole-leaf kratom, not the concentrated synthetic form known as 7-OH.

Keep reading

RFK Jr. Takes A Page From The Prohibitionist Playbook By Endorsing Criminalization Of Kratom Compound 7-OH

At a recent press conference, secretary of the U.S. Department of Health and Human Services (HHS) Robert F. Kennedy Jr. endorsed the Food and Drug Administration’s (FDA) recommendation to classify 7-hydroxymitragynine (7-OH) as a federally controlled substance. Despite political promises to forge a different path, the same tired Drug War tactics were on full display.

What Is 7-Hydroxymitragynine?

7-OH is one of many naturally occurring alkaloids found in the leaves of kratom trees. These leaves have been used for centuries as an herbal remedy. They contain a complex blend of alkaloids that interact with opioid, serotonin and alpha-adrenergic receptors. Around the world, people use kratom to help manage discomfort, enhance focus or relax.

In raw, dried kratom leaf, 7-OH exists only in trace amounts (typically less than 0.1 mg per gram of leaf). It’s formed when a more abundant alkaloid, mitragynine, degrades in the leaves.

But in recent years, manufacturers have begun converting large amounts of mitragynine into 7-OH to create extremely potent products. Some capsules and tablets contain 15–50 mg of 7-OH, hundreds of times more than what you’d find in a standard 2–5 gram serving of kratom leaves. 7-OH products produce stronger pain-killing effects than leaf kratom or kratom extract.

Yet potency, on its own, isn’t a problem. The problem is how these products are being manufactured, marketed and sold—with little to no safety testing, evidence for medical claims or manufacturing oversight.

7-OH manufacturing practices are often substandard, resulting in tablets that contain a range of unknown byproducts and impurities with substantial differences between batches. Oftentimes, manufacturers label them with kratom leaf imagery and terminology (such as “advanced kratom alkaloids,” “superior kratom alkaloids,” “premium kratom alkaloids” or “organic kratom extract full-spectrum 7-hydroxymitragynine”) with the clear intention to mislead consumers into thinking isolated 7-OH is similar to kratom.

Few come with clear dosage instructions, warnings about potential interactions or disclosures about dependency risks. And most are sold at gas stations and smoke shops, where employees typically have no education on the products or their potential risks.

What the Media and Government Get Wrong About 7OH

With growing popularity has come growing scrutiny. But government agencies and major media outlets aren’t focusing on the issues laid out above. Instead, the FDA, the Drug Enforcement Administration (DEA) and HHS are leaning on a familiar narrative predicated on fear: opioid = bad, synthetic = dangerous and availability = addiction.

None of these equations hold up under scrutiny. First, opioids have saved far more lives than they’ve taken—through pain management, trauma care and palliative medicine. The vast majority of opioid-related deaths involve combinations with other sedatives, not opioids alone.

Second, the natural vs. synthetic distinction tells us nothing meaningful about a drug’s safety. Consider nicotine (natural, widely available, highly addictive) versus naloxone (synthetic, life-saving, non-addictive).

And finally, while availability may shape patterns of use, it’s not what drives addiction. We don’t attribute alcoholism to the mere existence of alcohol—especially when younger generations are drinking less despite liquor stores on every corner. Nor do we assume that junk food availability is the sole cause of disordered eating. Addiction is about context, not presence.

So far, there is little evidence to support the HHS’s narrative that 7-OH is ruining lives. Many people do report issues with dependency and withdrawal, as well as financial issues from spending a lot of money on 7-OH products. But reports of severe 7-OH-related harms (like overdoses) are sparse. There’s currently no public record of a single verified death caused solely by 7-OH. At the same time, many individuals report success using 7-OH to manage conditions that they haven’t found any other viable treatment for.

Despite the lack of research into 7-OH and evidence of significant harm (and the nascent state of medical research), the FDA has formally recommended that 7-OH be added to Schedule I of the Controlled Substances Act. If approved, possession or production of 7-OH above a certain concentration would be a felony offense.

But placing a compound in Schedule I has historically done nothing to eliminate risk. In fact, we’ve often seen this categorization increase harm by pushing substances into the shadows, where they become harder to monitor, regulate, or use safely.

Keep reading

State Gives a Deadly Gift to Fentanyl Makers, Big Pharma, and Drug Warriors — A Ban on Kratom

This Friday, August 1, 2025, Louisiana will criminalize a leaf. Not fentanyl. Not meth. Not synthetic opioids that kill over 100,000 Americans every year. No, lawmakers have decided to outlaw kratom — a safe, natural plant in the coffee family — and those caught with it could face six months in jail and a $1,000 fine.

To understand the full weight of this insanity, you have to peel back the curtain on the drug war’s real purpose. It’s not about keeping people safe. It’s about criminalizing autonomy. It’s about corporate profits, institutional control, and punishing people for the crime of treating themselves outside of state-approved chemical dependency.

Kratom isn’t the threat. The threat is what it replaces.

The Lie That Keeps Killing

For years, scientists, doctors, and hundreds of thousands of kratom users have warned the federal government: ban this plant, and opioid deaths will rise.

In 2018, a group of scientists wrote to the DEA and White House, blasting the FDA’s push to classify kratom as a Schedule I drug. They made it clear: kratom, when used in its natural form, does not cause respiratory depression — the primary cause of death in opioid overdoses. More importantly, the plant has become a lifeline away from opioids for millions.

“Placing kratom into Schedule I will potentially increase the number of deaths of Americans caused by opioids,” the scientists warned, adding that the FDA’s data blaming kratom for dozens of deaths was riddled with inconsistencies, co-ingestions, and zero proof of causation.

In fact, many of those “kratom deaths” were linked to adulterated products, synthetic extracts, or pre-existing conditions — not the raw plant. One such alkaloid, 7-hydroxymitragynine (7-OH), has been artificially concentrated in some unregulated kratom extracts to mimic opioid-like effects, but this is not kratom. This is corporate bastardization — the same playbook used to demonize cannabis while pushing synthetic THC.

Keep reading

As Kratom Consumers Face Global Market Disruption, It’s Time For FDA To Put Safety Over Stigma

For over a decade, the U.S. Food and Drug Administration (FDA) has quietly crippled the kratom supply chain. Now, Indonesia’s new export regulations—meant to raise kratom quality standards and appeal to U.S. regulators—may have just squeezed the most responsible products out of the market.

At the end of 2024, the Indonesian government enacted sweeping new trade regulations aimed at tightening the export market for kratom, a tree native to Southeast Asia with leaves containing psychoactive alkaloids that have long been used as an herbal remedy.

One provision of the policy strengthens quality control for kratom exports, which was notably absent in the past. Moving forward, all kratom shipments must be sterilized before leaving Indonesia, and only batches that meet minimum thresholds for the concentration of the primary active compound, mitragynine, will qualify for export. These steps are designed to limit contamination and prevent exporters from bulking up shipments with non-kratom plant material.

The second component of the regulations is a prohibition on the export of raw kratom leaf with a particle size over 0.6 millimeters, which includes crushed-leaf kratom. In the United States, crushed leaf is most often used to make extracts. By imposing particle size restrictions, Indonesia aims to ensure that the economic value of processing raw kratom into finished extract products stays within its own borders, rather than being captured by foreign companies.

These new standards represent a step forward for kratom quality control and international industry fairness. The intentions are worth celebrating and supporting.

However, the new regulations have also inadvertently disrupted the supply chain of safer, more traditional kratom products while failing to address the root cause of regulatory tension between the U.S. and Indonesia.

Keep reading

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom.

FDA Deputy Commissioner for Policy, Legislation, and International Affairs Kimberlee Trzeciak discussed the agency’s cannabis and kratom interests during a webinar hosted by the Alliance for a Strong FDA this month.

Asked about issues that are “top of mind” for the agency in 2024 and where officials hope to engage with Congress, Trzeciak said that later this year or next year FDA wants to address setting up “an appropriate regulatory framework for CBD.”

Later in the conversation, the FDA official was asked specifically about how the agency is “prioritizing” its work on cannabis and kratom regulations, and she said officials are taking a number of factors into consideration as they work to address the substances.

“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” she said. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”

“Based on what we know about CBD in particular, we do not think that those products would be able to meet the safety standards that we have in place for foods and dietary supplements today,” she said, referencing the agency’s position after it declined to enact regulations for the non-intoxicating cannabinoid that was legalized under the 2018 Farm Bill.

“What can we do in terms of regulatory tools to ensure that this product is going to be marketed that consumers are clearly aware of what the product is, what is in it and making sure that we have basic information about the marketplace?” Trzeciak said. “I like to think of it as the common regulatory tool that we have across the other products that we regulate.”

She added that FDA wants to “work with Congress on this effort,” including possible rulemaking around CBD product labeling and packaging.

“For example, how can we ensure that the agency knows if there are adverse events that are being reported, so we can identify those trends, making sure that the product is being manufactured or produced in a way that’s safe and quality?” she said.

Kratom reform advocates say the deputy commissioner’s comments represent a “shift” in the agency’s policy perspective on the issue. Historically, FDA hasn’t engaged in the kratom debate as actively as other agencies such as the National Institute on Drug Abuse (NIDA).

Keep reading

Industry group calls for FDA regulation of Kratom

Kratom, the tropical tree native to Southeast Asia, isn’t lawfully marketed in the U.S.— not as a drug product, a dietary supplement, or a food additive in conventional food. However, products prepared from kratom leaves are available in the U.S. through sales on the Internet and at brick-and-mortar stores. 

Kratom is often used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal.

According to the American Kratom Association, the U.S. Food and Drug Administration is putting consumers at risk because it refuses to regulate kratom properly.  

Mac Haddow, the association’s senior fellow on public policy, says: “Since the FDA  treats all kratom products as the same, consumers have to navigate an increasingly complex marketplace alone.”

Keep reading

Top Federal Health Official And Former White House Drug Czar Brief Congress On Kratom As Advocates Push For Bipartisan Reform Bill

A top federal health official and a former White House drug czar were among the featured speakers at a recent kratom-focused congressional briefing, laying out research priorities for the plant and broadly promoting alternative approaches to drug criminalization.

Last week’s event, organized by the American Kratom Association (AKA), was meant to give a science-based overview of kratom issues for congressional staff and stakeholders as bipartisan lawmakers work to advance a bill to federally regulate the substance, which is currently unscheduled and anecdotally used for pain relief, curbing withdrawal symptoms and other purposes.

National Institute on Drug Abuse (NIDA) Director Nora Volkow started by saying that while she always wants policy to be grounded in science, she’s come to understand that data is “not necessarily sufficient or enough.”

In the case of kratom, she said, “unfortunately, we don’t know much,” which is why NIDA is committed to expanding research into its potential risks and benefits. For example, she said health agencies have “invested significant resources” to synthesize the main compound of kratom so that researchers can conduct clinical trials investigating how it can be used for pain management and also “for the treatment of drug addiction.”

Keep reading

Indonesia’s President Urges Biden To Lift FDA’s Kratom Import Restrictions, Advocacy Groups Say

In a meeting with President Joe Biden this week, the president of Indonesia urged the administration to lift a Food and Drug Administration (FDA) alert that broadly restricts imports of kratom to the U.S., according to a pair of advocacy groups.

Indonesia is one of the primary international exporters of kratom, a plant native to Southeast Asia that’s used for pain relief, managing the symptoms of opioid withdrawal and other purposes. The plant is currently unscheduled under U.S. law, but FDA issued an import alert in July that has seriously limited kratom imports from Canada, Indonesia, Malaysia and the Philippines.

Indonesian President Joko Widodo met with Biden for a bilateral meeting at the White House on Monday. According to the American Kratom Association (AKA) and the Kratom Coalition, Widodo used the opportunity to request administrative action to remove the FDA restrictions, emphasizing the economic and environmental consequences of the current kratom import policy for Indonesia.

The White House referred Marijuana Moment’s request for comment to the National Security Council (NSC). A spokesperson for NSC said they have “nothing to add on the Leaders’ conversation beyond the joint statement and fact sheet released on Monday” that do not explicitly mention kratom.

Keep reading

Federal Lawmakers Are Preparing To Reintroduce Legislation To Regulate Kratom Amid Pushback To FDA-Proposed Ban

As federal lawmakers prepare to reintroduce a bill to regulate kratom, a former Trump administration drug czar stressed the need to beat back “misinformation” from the Food and Drug Administration (FDA), which has attempted to ban the substance in the U.S. and abroad.

Members of the American Kratom Association (AKA) said during a webinar Tuesday that they expect federal legislation to regulate the drug “will be filed shortly” in Congress and could be taken up later this session.

The text of the forthcoming bill “will be word-for-word the same” as congressional legislation introduced last session, said Mac Haddow, a senior fellow at AKA. The title, however, will be updated to the Kratom Consumer Protection Act, a nod to model legislation that AKA has been lobbying for at the state and federal levels.

Sponsors will include, on the Senate side, Sens. Mike Lee (R-UT) and Cory Booker (D-NJ), who also sponsored last session’s bill, the Federal Clarity for Kratom Consumers Act. In the House, lead sponsors will be Reps. Mark Pocan (D-WI) and Jack Bergman (R-MI). Pocan sponsored last year’s bill in the House, while Bergman is a new addition.

The forthcoming legislation’s bipartisan sponsorship in each chamber—specifically pairing a “very liberal” elected official with a “very conservative” one—is designed to highlight “that this is not a partisan issue,” Haddow said. “This is about good policy.”

If the bill becomes law, it would require FDA to take further steps to evaluate the health and safety of kratom and would also prohibit the agency from regulating kratom products in a way that’s more restrictive than regulations for food or dietary supplements.

Neither chamber took action on the proposal last session, but AKA expects more traction—and more sponsors—on this year’s bill.

Keep reading